First Time Loading...
I

IX Biopharma Ltd
SGX:42C

Watchlist Manager
IX Biopharma Ltd
SGX:42C
Watchlist
Price: 0.042 SGD 2.44% Market Closed
Updated: Apr 27, 2024

Intrinsic Value

iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. [ Read More ]

The intrinsic value of one 42C stock under the Base Case scenario is 0.275 SGD. Compared to the current market price of 0.042 SGD, IX Biopharma Ltd is Undervalued by 85%.

Key Points:
42C Intrinsic Value
Base Case
0.275 SGD
Undervaluation 85%
Intrinsic Value
Price
I
Worst Case
Base Case
Best Case

Valuation Backtest
IX Biopharma Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling 42C stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
IX Biopharma Ltd

Provide an overview of the primary business activities
of IX Biopharma Ltd.

What unique competitive advantages
does IX Biopharma Ltd hold over its rivals?

What risks and challenges
does IX Biopharma Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for IX Biopharma Ltd.

Provide P/S
for IX Biopharma Ltd.

Provide P/E
for IX Biopharma Ltd.

Provide P/OCF
for IX Biopharma Ltd.

Provide P/FCFE
for IX Biopharma Ltd.

Provide P/B
for IX Biopharma Ltd.

Provide EV/S
for IX Biopharma Ltd.

Provide EV/GP
for IX Biopharma Ltd.

Provide EV/EBITDA
for IX Biopharma Ltd.

Provide EV/EBIT
for IX Biopharma Ltd.

Provide EV/OCF
for IX Biopharma Ltd.

Provide EV/FCFF
for IX Biopharma Ltd.

Provide EV/IC
for IX Biopharma Ltd.

Show me price targets
for IX Biopharma Ltd made by professional analysts.

What are the Revenue projections
for IX Biopharma Ltd?

How accurate were the past Revenue estimates
for IX Biopharma Ltd?

What are the Net Income projections
for IX Biopharma Ltd?

How accurate were the past Net Income estimates
for IX Biopharma Ltd?

What are the EPS projections
for IX Biopharma Ltd?

How accurate were the past EPS estimates
for IX Biopharma Ltd?

What are the EBIT projections
for IX Biopharma Ltd?

How accurate were the past EBIT estimates
for IX Biopharma Ltd?

Compare the revenue forecasts
for IX Biopharma Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of IX Biopharma Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of IX Biopharma Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of IX Biopharma Ltd compared to its peers.

Compare the P/E ratios
of IX Biopharma Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing IX Biopharma Ltd with its peers.

Analyze the financial leverage
of IX Biopharma Ltd compared to its main competitors.

Show all profitability ratios
for IX Biopharma Ltd.

Provide ROE
for IX Biopharma Ltd.

Provide ROA
for IX Biopharma Ltd.

Provide ROIC
for IX Biopharma Ltd.

Provide ROCE
for IX Biopharma Ltd.

Provide Gross Margin
for IX Biopharma Ltd.

Provide Operating Margin
for IX Biopharma Ltd.

Provide Net Margin
for IX Biopharma Ltd.

Provide FCF Margin
for IX Biopharma Ltd.

Show all solvency ratios
for IX Biopharma Ltd.

Provide D/E Ratio
for IX Biopharma Ltd.

Provide D/A Ratio
for IX Biopharma Ltd.

Provide Interest Coverage Ratio
for IX Biopharma Ltd.

Provide Altman Z-Score Ratio
for IX Biopharma Ltd.

Provide Quick Ratio
for IX Biopharma Ltd.

Provide Current Ratio
for IX Biopharma Ltd.

Provide Cash Ratio
for IX Biopharma Ltd.

What is the historical Revenue growth
over the last 5 years for IX Biopharma Ltd?

What is the historical Net Income growth
over the last 5 years for IX Biopharma Ltd?

What is the current Free Cash Flow
of IX Biopharma Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for IX Biopharma Ltd.

Financials

Balance Sheet Decomposition
IX Biopharma Ltd

Current Assets 9.8m
Cash & Short-Term Investments 6.1m
Receivables 2.4m
Other Current Assets 1.3m
Non-Current Assets 8.5m
Long-Term Investments 88k
PP&E 8m
Intangibles 302k
Other Non-Current Assets 187k
Current Liabilities 7.1m
Accounts Payable 3.1m
Other Current Liabilities 3.9m
Non-Current Liabilities 3.6m
Long-Term Debt 2.9m
Other Non-Current Liabilities 666k
Efficiency

Earnings Waterfall
IX Biopharma Ltd

Revenue
6.1m SGD
Cost of Revenue
-4m SGD
Gross Profit
2m SGD
Operating Expenses
-8.6m SGD
Operating Income
-6.6m SGD
Other Expenses
-3m SGD
Net Income
-9.6m SGD

Free Cash Flow Analysis
IX Biopharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

42C Profitability Score
Profitability Due Diligence

IX Biopharma Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
Positive Gross Profit
ROIC is Increasing
26/100
Profitability
Score

IX Biopharma Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

42C Solvency Score
Solvency Due Diligence

IX Biopharma Ltd's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
39/100
Solvency
Score

IX Biopharma Ltd's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

42C Price Targets Summary
IX Biopharma Ltd

Wall Street analysts forecast 42C stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 42C is 0.25 SGD .

Lowest
Price Target
Not Available
Average
Price Target
0.25 SGD
495% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

42C Price
IX Biopharma Ltd

1M 1M
-21%
6M 6M
+5%
1Y 1Y
-49%
3Y 3Y
-83%
5Y 5Y
-81%
10Y 10Y
-92%
Annual Price Range
0.042
52w Low
0.038
52w High
0.1
Price Metrics
Average Annual Return -10.51%
Standard Deviation of Annual Returns 21.04%
Max Drawdown -100%
Shares Statistics
Market Capitalization 32.3m SGD
Shares Outstanding 768 317 356
Percentage of Shares Shorted
N/A

42C Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

IX Biopharma Ltd

Country

Singapore

Industry

Pharmaceuticals

Market Cap

32.3m SGD

Dividend Yield

0%

Description

iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.

Contact

1 Kim Seng Promenade, #14-01 Great World City
+6562352270
http://www.ixbiopharma.com/

IPO

2015-07-22

Employees

-

Officers

Chief Pharmacist
Prof. Chin Beng Lim
Executive Chairman & CEO
Mr. Yip Hang Lee
Chief Financial Officer
Mr. Sien Lup Chew
COO & Chief Medical Officer
Dr. Janakan Krishnarajah
Chief Scientist
Dr. Iain Bruce Cook
Chief Commercial Officer
Ms. Eva Tan
Show More
Secretary
Ms. Soo Fern Lee ACIS
Show Less

See Also

Discover More
What is the Intrinsic Value of one 42C stock?

The intrinsic value of one 42C stock under the Base Case scenario is 0.275 SGD.

Is 42C stock undervalued or overvalued?

Compared to the current market price of 0.042 SGD, IX Biopharma Ltd is Undervalued by 85%.